Safety of direct- acting oral anticoagulant (DOAC) prescribing: OpenSAFELY- TPP analysis of 20.5 million adults' electronic health records

被引:1
作者
Homan, Karen [1 ]
Seeley, Rachel [1 ]
Fisher, Louis [1 ]
Khatri, Sajida [1 ]
Smith, Katie [1 ]
Jamieson, Tony [2 ]
Speed, Victoria [3 ]
Roberts, Carol A. [1 ]
Mehrkar, Amir [3 ]
Bacon, Sebastian [3 ]
Mackenna, Brian [3 ]
Goldacre, Ben [3 ]
机构
[1] PrescQIPP CIC, London, England
[2] NHS England, Med Safety Improvement Programme, London, England
[3] Univ Oxford, Bennett Inst Appl Data Sci, Nuffield Dept Primary Care Hlth Sci, Oxford, England
基金
美国国家卫生研究院; 英国惠康基金; 英国科研创新办公室;
关键词
DOAC; creatinine clearance; COVID-19; patient safety; electronic health records;
D O I
10.3399/BJGPO.2023.0163
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: During the COVID- 19 pandemic many patients were switched from warfarin to direct- acting oral anticoagulants (DOACs), which require the creatinine clearance (CrCl) calculated to ensure the correct dose is prescribed to avoid bleeding or reduced efficacy. Aim: To identify the study population proportion prescribed a DOAC. Of these, the proportion with recorded: weight, estimated glomerular filtration rate (eGFR), creatinine, CrCl and atrial fibrillation (AF). To analyse the proportion of patients with recorded AF and CrCl prescribed a recommended DOAC dose. Design & setting: A retrospective cohort study of 20.5 million adult NHS patients' electronic health records (EHRs) in England in the OpenSAFELY- TPP platform (January 2018-February 2023). Method: Patients on DOACs were analysed for age, sex, recorded weight, eGFR, creatinine, CrCl and AF. Prescribed DOAC doses in patients with recorded AF were compared with recommended doses for recorded CrCl and determined as either recommended, higher than recommended (overdose), or lower than recommended (underdose). Results: In February 2023, weight, eGFR, creatinine, CrCl, and AF were recorded in 72.8%, 92.4%, 94.3%, 73.5%, and 73.9% of study population, respectively. Both AF and CrCl were recorded for 56.7% of patients. Of these, 86.2% received the recommended, and 13.8% non- recommended, DOAC doses. Conclusion: CrCl is not recorded for a substantial number of patients on DOACs. We recommend that national organisations tasked with safety, collectively update guidance on the appropriate weight to use in the Cockcroft-Gault equation, clarify that CrCl is not equivalent to eGFR, and work with GP clinical system suppliers to standardise the calculation of CrCl in the EHR.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 21 条
  • [1] Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting
    Afzal, Saima
    Zaidi, Syed Tabish Razi
    Merchant, Hamid A.
    Babar, Zaheer-Ud-Din
    Hasan, Syed Shahzad
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (02) : 646 - 653
  • [2] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [3] OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
    Curtis, Helen J.
    MacKenna, Brian
    Walker, Alex J.
    Croker, Richard
    Mehrkar, Amir
    Morton, Caroline
    Bacon, Seb
    Hickman, George
    Inglesby, Peter
    Bates, Chris
    Evans, David
    Ward, Tom
    Cockburn, Jonathan
    Davy, Simon
    Bhaskaran, Krishnan
    Schultze, Anna
    Rentsch, Christopher T.
    Williamson, Elizabeth
    Hulme, William
    Tomlinson, Laurie
    Mathur, Rohini
    Drysdale, Henry
    Eggo, Rosalind M.
    Wong, Angel Yun
    Forbes, Harriet
    Parry, John
    Hester, Frank
    Harper, Sam
    Douglas, Ian
    Smeeth, Liam
    Goldacre, Ben
    [J]. OPEN HEART, 2021, 8 (02):
  • [4] Department of Health and Social Care, 2022, [Withdrawn] Coronavirus (COVID- 19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 - general
  • [5] Erskine David, 2019, Drug Ther Bull, V57, P50, DOI 10.1136/dtb.2019.000013
  • [6] Potentially inappropriate prescribing of DOACs to people with mechanical heart valves: A federated analysis of 57.9 million patients' primary care records in situ using OpenSAFELY
    Fisher, Louis
    Speed, Victoria
    Curtis, Helen J.
    Rentsch, Christopher T.
    Wong, Angel Y. S.
    Schultze, Anna
    Massey, Jon
    Inglesby, Peter
    Morton, Caroline E.
    Wood, Marion
    Walker, Alex J.
    Morley, Jessica
    Mehrkar, Amir
    Bacon, Seb
    Hickman, George
    Bates, Chris
    Croker, Richard
    Evans, David
    Ward, Tom
    Cockburn, Jonathan
    Davy, Simon
    Bhaskaran, Krishnan
    Smith, Becky
    Williamson, Elizabeth
    Hulme, William
    Green, Amelia
    Eggo, Rosalind M.
    Forbes, Harriet
    Tazare, John
    Parry, John
    Hester, Frank
    Harper, Sam
    Meadows, Jonathan
    O'Hanlon, Shaun
    Eavis, Alex
    Jarvis, Richard
    Avramov, Dima
    Griffiths, Paul
    Fowles, Aaron
    Parkes, Nasreen
    Douglas, Ian J.
    Evans, Stephen J. W.
    Smeeth, Liam
    MacKenna, Brian
    Tomlinson, Laurie
    Goldacre, Ben
    [J]. THROMBOSIS RESEARCH, 2022, 211 : 150 - 153
  • [7] Joint formulary committee, 2024, british national formulary for children
  • [8] Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database
    Khachatryan, Artak
    Doobaree, Indraraj Umesh
    Spentzouris, George
    Gusto, Gaelle
    Zawaneh, Yousef
    Mughal, Farhan
    Anastassopoulou, Anastassia
    Manu, Marius
    Fay, Matthew
    [J]. ADVANCES IN THERAPY, 2023, 40 (02) : 504 - 520
  • [9] Medicines and Healthcare products Regulatory Agency, 2019, Drug Safety Update, V13, P3
  • [10] Medicines and Healthcare products Regulatory Agency, 2020, Drug Safety Update, V13, P2